Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD 13)

Nature Biotechnology

Volumn 18, Issue 11, 2000, Pages 1185-1190

  Curnis, F ^a   Sacchi, A ^a   Borgna, L ^a   Magni, F ^a   Gasparri, A ^a   Corti, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Aminopeptidase N CD13; Angiogenesis; Immunotherapy; Tumor necrosis factor; Tumor targeting; Vascular targeting

Indexed keywords

HYBRID PROTEIN; MELPHALAN; MICROSOMAL AMINOPEPTIDASE; NGR TNF; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL STRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; HUMAN; LD 50; LIGAND BINDING; LYMPHOMA; MELANOMA; MOLECULAR HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD13; CELL LINE; CELL SEPARATION; CHROMATOGRAPHY, GEL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LIGANDS; LYMPHOMA; MASS SPECTROMETRY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

ANIMALIA; MURINAE;

EID: 0033764170     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/81183     Document Type: Article

References (35)

1. Biologic therapy with TNF: Preclinical studies
2. An endotoxin-induced serum factor that causes necrosis of tumors
3. Biologic therapy with TNF: Systemic administration and isolation perfusion
4. High-dose resombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
5. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonreseotable extremity soft tissue sarcomas: A multicenter trial
6. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study
7. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
8. Tumour necrosis factor: Strategies for improving the therapeutic index
9. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models
10. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas
11. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
12. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: Induction of tumor-specific immunity
13. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin
14. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
15. Alpha v integrins as receptors for tumor targeting by circulating ligands
16. Tumor targeting with a selective gelatinase inhibitor
17. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
18. The active form of tumor necrosis factor is a trimer
19. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha
20. A mouse aminopeptidase N is a marker for antigen-presenting cells and appears to be co-expressed with major histocompatibility complex class II molecules
21. Aminopeptidases: Structure and function
22. Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key
23. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice
24. Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells
25. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors
26. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities
27. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferongamma and melphalan in isolation perfusion
28. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion
29. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
30. Tumor targeting with biotinylated tumor necrosis factor alpha: Structure-activity relationships and mechanism of action on avidin pretargeted tumor cells
31. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism
32. Demonstration of immunogenicity with the poorly immunogenic B16 melanoma
33. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor
34. Tumor necrosis factor (TNF) alpha quantification by ELISA and bioassay: Effects of TNF alpha-solubre TNF receptor (p55) complex dissociation during assay incubations
35. Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain